Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sennosid A + sennosid B is a combination of two natural dianthrone glycosides, the primary active components found in senna (Cassia species) and rhubarb. This combination is used as a stimulant laxative for the short-term treatment of constipation and for bowel cleansing before medical procedures. The mechanism involves metabolism by gut bacteria to active metabolites (notably rheinanthrone), which increase prostaglandin E2 via cyclooxygenase 2 expression, decrease aquaporin 3 expression in colonic mucosa, restrict water reabsorption, and stimulate peristalsis in the large intestine. These effects result in increased fecal water content and promote bowel movements within 6–12 hours after administration[1][2][5]. Sennoside A may also have additional pharmacological activities such as anti-obesity, hypoglycemic, hepatoprotective, anti-inflammatory, anti-tumor, antibacterial, antifungal, antiviral, and neuroprotective effects; however these are not primary indications[5]. Long-term or high-dose use can cause adverse effects including melanosis coli.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sennosid A + sennosid B.